Historical version

This is version 3, as it stood on . It is not what this organization currently publishes — read the current version.

[SHINSA]Points to Consider for the Development of Companion Diagnostics Developed in Parallel with Anti-cancer Drugs(Early Consideration) and Quality-Related Considerations for Human Cell-Derived Extracellular Vesicle (EV) Products at the Time of Initial Clinical Trial Notification (Early Consideration) posted.

Imported from official source

This version

Version
3 of 5
Recorded
October 19, 2026 00:32
Change
Imported change
Content hash
5419ee49d7f5c3184f889c670ea25446
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.